Manufacturing Compliance Updates In Brief From US FDA and EU
Executive Summary
Recent US FDA drug GMP warning letters target data integrity issues, inadequate sterility practices and inadequate testing of raw materials and finished products at firms in Japan, Hong Kong, China, Italy and the US; FDA adds one drug GMP import alert; and EU GMP noncompliance notice goes to Kadam Exports in India for deficient manufacturing conditions.
You may also be interested in...
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
2020 In Review: Despite Pandemic, The US FDA Issued Just 20% Fewer Drug GMP Warning Letters
The US FDA managed to issue 94 drug GMP warning letters last year despite the pandemic, with fewer expected for 2021. Top issue areas included lack of sterility assurance, nitrosamine impurities, poor data integrity and basic GMP failures.
US FDA Still “Actively” Drafting Proposed Licensing Rule For Wholesalers and 3PLs
Pharmaceutical manufacturers should have already begun serializing products and verifying saleable returns to comply with DSCSA, says FDA official who also asserted that licensing standards for wholesale distributors and third-party logistics providers will be forthcoming. This rule is already six years overdue under a DSCSA mandated timeline.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: